![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Pharmacology, Department of Biomedical Sciences and Biotechnology and Centre of Excellence on Diagnostic and Therapeutic Innovation, University of Brescia, Brescia, Italy (C.F., M.C.R., C.B., S.B., G.C., P.F.S., C.M.); and Istituto di Ricovero e Cura a Carattere Scientifico, Venezia, Italy (P.F.S., C.M.)
Glutamate-mediated mechanisms are related to the motor complications of L-DOPA therapy in Parkinson's disease (PD). In striatal postsynaptic densities (PSD), the dopamine D1 receptor (D1R) is part of an oligomeric complex with the glutamate N-methyl-D-aspartate receptor (NMDAR), determining the strength of corticostriatal transmission. We studied D1R/NMDAR complex alterations induced by L-DOPA in the 6-hydroxydopamine-lesioned rat model of PD. L-DOPA-treated hemiparkinsonian rats were determined to be dyskinetic or nondyskinetic based on behavioral testing. D1R/NMDAR assemblies containing NR1-C2 and NR2B subunits were decreased in the PSD of lesioned striatum. Short-term L-DOPA administration improved akinesia and restored the synaptic abundance of D1R, NR1-C2 and NR2B. Prolonged L-DOPA treatment also normalized synaptic D1R/NMDAR complexes in nondyskinetic rats, but remarkably reduced them in the dyskinetic group without changing their interaction. This decrease involved NR1-C2, NR1-C2', NR2A, and NR2B subunits. The composition of residual synaptic D1R/NMDAR complexes in dyskinetic rats may thus be different from that observed in lesioned rats, suggesting that expression of different motor dysfunctions might be related to the receptor profile at corticostriatal synapses. The levels of D1R/NMDAR complexes were unchanged in total striatal membrane proteins, suggesting that the decrease of these species in the PSD is likely to reflect an altered receptor trafficking. In human embryonic kidney 293 cells expressing the D1R/NMDAR, complex costimulation of both D1R and NMDAR, but not individual receptor activation, promoted internalization, suggesting that development of dyskinesias might be related to agonist-mediated down-regulation of the D1R/NMDAR complex at corticostriatal synapses.
Address correspondence to: Cristina Missale, Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Viale Europa 11, 25124 Brescia, Italy. E-mail: cmissale{at}med.unibs.it
This article has been cited by other articles:
|
|
 |
|
  A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. D. Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, October 24, 2008; (2008) awn235v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bordia, C. Campos, L. Huang, and M. Quik Continuous and Intermittent Nicotine Treatment Reduces L-3,4-Dihydroxyphenylalanine (L-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 239 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tong and A. J. Gibb Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum J. Physiol., October 1, 2008; 586(19): 4693 - 4707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oueslati, V. Sgambato-Faure, C. Melon, P. Kachidian, P. Gubellini, M. Amri, L. K.-L. Goff, and P. Salin High-Frequency Stimulation of the Subthalamic Nucleus Potentiates L-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease J. Neurosci., February 28, 2007; 27(9): 2377 - 2386. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
